A Study to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of VH3739937 in in Treatment-Naive Adults Living With HIV-1: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for A Study to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of VH3739937 in in Treatment-Naive Adults Living With HIV-1 (NCT06061081), a randomized phase 2 study. The primary outcome is Maximum Change From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA)..

2. Clinical Question

3. Trial Design

This was a randomized, placebo-controlled, parallel-group phase 2 study. The official title describes it as adaptive and double-blind, with the sponsor unblinded; the registry classifies masking as quadruple. The record does not explain how the adaptive features operated or which roles were masked. Allocation details beyond randomization are not reported in the registry record.

The study evaluated three VH3739937 dosing schedules and two placebo schedules. Participants in the low-dose group received a loading dose on Day 1, then once-daily maintenance dosing from Days 2 through 7. The medium-dose group followed the same broad schedule, with its own loading and maintenance doses. The high-dose group received a single dose on Day 1. Placebo participants received either daily dosing through Day 7 or a single dose on Day 1. The registry record states that participants transitioned to standard-of-care combination antiretroviral therapy on Day 8 and continued assessments through Day 25.

The study started on 2023-12-21, and the primary completion date was 2024-08-27. Its status is terminated. The reason for termination, whether the planned study activities were completed as intended, and whether any protocol changes followed termination are not reported in the registry record. The enrollment recorded is 21. The arm-level primary outcome results are based on groups of different sizes, including placebo groups with one participant each, so the precision of the descriptive summaries is not comparable across arms.

The primary purpose stated in the record was to assess antiviral activity during monotherapy in treatment-naive adults with HIV-1. The stated primary endpoint covers Day 1 through Day 8, before the listed transition to standard-of-care treatment. The record also lists safety, tolerability, and pharmacokinetic objectives, but the posted primary endpoint results do not by themselves answer all of those questions.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Before assignment: This study was terminated due to Sponsor decision.

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: The analysis was performed on the full analysis set (FAS) which included all randomized participants who received at least one full dose of study treatment. Only participants with data available at the specified timepoints were included in this analysis.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Maximum Change From Baseline in Plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA)., measured over From Day 1 to Day 8.

The primary endpoint is the maximum change from baseline in plasma HIV-1 RNA, measured in copies/milliliter, from Day 1 to Day 8. For each participant, the registry defines this as baseline value minus the lowest post-dose value observed through Day 8, inclusive. Baseline is the most recent valid, non-missing pre-dose assessment, including an unscheduled visit if applicable.

Plasma HIV-1 RNA is a continuous measure of viral concentration. Tracking its change over a defined interval gives a numerical description of short-term antiviral activity during the study dosing period. Because the endpoint uses the lowest post-dose measurement in the interval, it represents the maximum observed change rather than a change at one fixed visit. That choice also means the endpoint depends on the scheduled and available measurements within the interval.

The registry reports the arm-level mean and identifies standard deviation as the dispersion measure. A negative mean change, under the registry’s stated calculation, indicates that the lowest post-dose value was higher than baseline on average; a positive change would indicate a lower post-dose value than baseline. The reported arm means are negative. Interpretation should stay focused on this defined short-term measure: it is not a summary of later HIV-1 RNA values, outcomes after the study period, or the effects of longer-term treatment.

The analysis included the full analysis set as defined in the record, with only participants having data at the specified timepoints. How missing measurements affected the endpoint beyond that inclusion rule is not reported in the registry record.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The registry reports a continuous primary endpoint and summarizes it using the mean and standard deviation. These statistics answer different descriptive questions. The mean is the arithmetic average of the observed endpoint values in an arm. The standard deviation describes how spread out individual values are around that average. It is not the uncertainty of the mean and is not a confidence interval. A confidence interval, when reported, would communicate a range of values compatible with the data and the chosen method; no such interval is reported for these endpoint summaries.

How is the endpoint constructed?

The endpoint is the maximum change from baseline through Day 8, inclusive. The registry identifies the lowest post-dose HIV-1 RNA measurement in that interval and subtracts it from baseline. Baseline is the most recent valid pre-dose value, including a measurement from an unscheduled visit. Since the calculation is baseline minus the lowest post-dose value, the sign has a specific meaning: a negative result indicates that the lowest post-dose measurement was numerically above baseline. A general caution for continuous outcomes is that changing the order of subtraction reverses the sign, so the registry’s formula should guide interpretation.

Selecting the lowest observed post-dose value makes the endpoint a maximum-change measure over the assessment window rather than a comparison at one fixed post-dose time. In general, a measure based on an extreme value can be sensitive to the timing and availability of assessments. The record describes the calculation but does not report how many measurements each participant contributed or whether assessment timing differed across participants.

What do the group summaries tell us?

The arm means give descriptive averages, while the standard deviations give information about participant-level spread. The posted standard deviations for the VH3739937 groups indicate variation around each mean. With small groups, a mean can be affected by individual observations, and the standard deviation itself may be imprecisely estimated. The placebo groups each have one participant, so a within-group standard deviation cannot be estimated from the posted data. These features make the arm-level summaries unsuitable as a substitute for a formal comparison with quantified uncertainty.

In general, a confidence interval for a group mean and a confidence interval for a difference between groups answer distinct questions. An interval for a mean describes uncertainty in that arm’s average; an interval for a difference addresses comparative uncertainty. Neither is reported for the primary endpoint. The registry also reports zero analysis entries, so no model-based adjustment, hypothesis test, or comparative estimate is available in the posted analysis record.

What is the role of the analysis population?

The primary analysis population is the full analysis set, defined as all randomized participants who received at least one full dose of study treatment. The record further says that only participants with data available at the specified timepoints were included in this analysis. This is the stated rule for the endpoint population; the record does not provide a flow of participants through randomization, dosing, and endpoint analysis, or a detailed account of missing measurements.

In general, missing data can affect a summary if the participants with observed measurements differ from those without them. The record does not state whether missing values were imputed, whether sensitivity analyses were conducted, or how incomplete data at intermediate assessments were handled when selecting the lowest post-dose value. These methods are not reported in the registry record and should not be inferred from the analysis population definition alone.

What do the planning illustrations mean?

The registry’s sample-size assumptions describe planning illustrations based on the observed effect, not the trial’s own design. They use a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation; the effect to detect is expressed as a stated fraction of the observed effect. For non-time-to-event outcomes, the planning figures are participants per arm for 80% power or 90% power, where such figures are available. No planning values for this endpoint are reported as estimable: the record notes missing or non-estimable values for a two-arm comparison of this continuous endpoint.

These illustrations, when available, are not observed power and do not show the probability that the completed trial detected an effect. They are conditional calculations using chosen assumptions. The observed effect used as a planning basis may itself be uncertain, particularly with small groups. The record does not report the protocol’s sample-size justification, the intended target for enrollment, or the statistical rationale for the study’s arm structure. Those design details are not reported in the registry record.

More generally, continuous data can be skewed or contain influential observations; a mean and standard deviation do not reveal the full distribution. Over-dispersion, in general, means variability is greater than a model expects, which can make standard errors and tests unreliable if the model does not account for it. The registry record does not report a distributional assessment or a model for this endpoint, so neither skewness nor over-dispersion can be assessed from the posted summaries alone.

10. Multiplicity, Missing Data and Analysis Populations

The registry lists 16 outcome measures and 15 posted secondary outcomes. The secondary outcomes include safety measures and pharmacokinetic measures such as maximum observed concentration, time to maximum concentration, concentration at 24 hours, and area under the concentration-time curve. The record does not report a multiplicity procedure for interpreting several outcomes or comparisons. It also does not report interim analysis details, despite the adaptive wording in the official title. Whether interim analyses or multiplicity adjustments were planned is not reported in the registry record.

The registry lists zero analysis entries. No primary endpoint confidence interval, p-value, or comparative model result is posted. Therefore, there is no reported inferential result to interpret as adjusted or unadjusted, and no multiplicity-adjusted claim can be assessed. The registry’s planning assumptions concern hypothetical sample-size illustrations; they do not supply a test of the posted arm differences.

For the primary endpoint, the stated population is the full analysis set: randomized participants who received at least one full dose. Only participants with data available at the specified timepoints were included. The record does not describe imputation, a missing-data sensitivity analysis, or a detailed accounting of endpoint availability by arm. It also does not state how missing measurements affected the choice of the lowest post-dose value. These missing-data methods are not reported in the registry record.

Because both multiplicity handling and detailed missing-data methods are unavailable, the arm means are best read as descriptive summaries. The data do not support reconstructing an unreported testing strategy or assuming that all planned comparisons were conducted.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: upper respiratory tract infection (16.7%).

The safety results list participants at risk and participants affected by serious and other adverse events in each group. In the VH3739937 low-dose group, 0 participants had a serious adverse event and 3 had other adverse events, with 7 at risk for each measure. In the medium-dose group, 1 participant had a serious adverse event and 2 had other adverse events, with 6 at risk. In the high-dose group, 0 participants had a serious adverse event and 5 had other adverse events, with 6 at risk. In each placebo group, 0 participants had serious or other adverse events, with 1 at risk.

The registry lists Upper Respiratory Tract Infection as the top serious adverse-event term, with 16.7%. The group results also report 0 deaths in every group. These counts describe what was recorded during the study; they do not establish that an event was caused by study treatment. The registry does not provide a comparative safety analysis, and the small groups—particularly the placebo groups—make the counts difficult to compare. No conclusion about relative safety should be drawn from these descriptive figures alone.

12. What the Result Does, and Does Not, Mean

The primary endpoint results describe maximum change from baseline in plasma HIV-1 RNA through Day 8 in the analyzed groups. The registry reports means and standard deviations for the VH3739937 dose groups, and means for the two placebo groups. The endpoint is short-term and uses each participant’s lowest post-dose value in the assessment window, so it is not equivalent to a result at a single fixed visit or to a longer-term outcome.

The posted values do not establish a comparative treatment effect. There are no reported confidence intervals, p-values, or model-based comparisons, and the placebo groups each contain one participant. This means the numerical differences between arm means cannot be interpreted as reliable evidence of a difference between treatments. The standard deviations in the VH3739937 groups also show that individual values varied around the group averages.

The results do not establish what happened after the study’s primary endpoint window, whether changes persisted, or how the groups would compare under longer-term treatment. Participants transitioned to standard-of-care combination antiretroviral therapy on Day 8 and continued assessments through Day 25, but the posted primary endpoint is defined only through Day 8. No later efficacy results are included in the registry record reported for this page.

The safety counts are also descriptive. They do not identify causation, and the registry record does not report a comparative safety analysis. The absence of a recorded event in a small group should not be taken as proof that an event cannot occur. The record’s terminated status does not explain why the trial ended, and it should not be interpreted as an efficacy or safety finding.

In short, the registry provides a limited account of short-term endpoint summaries and adverse-event counts. It does not provide the inferential analyses or follow-up information needed to make broader claims about comparative effects, longer-term outcomes, or overall benefit and risk.

13. Why This Trial Matters Statistically

This trial is statistically notable because it places several dosing schedules and two placebo schedules in one randomized study, while the primary results are reported as arm-level summaries without comparative inference. The result is an example of why descriptive means need to be read alongside group sizes, variability, and the analysis population. The placebo groups each have one participant, whereas the VH3739937 groups have more observations; this imbalance and sparsity limit how informative direct numerical contrasts can be.

The endpoint is also constructed using an extreme value: the lowest post-dose RNA measurement through Day 8. This makes the outcome directly tied to the observation window and the available measurements. It illustrates a general statistical point: an endpoint’s definition—including how baseline is chosen, which visits count, and whether the outcome is a minimum or maximum—can shape what the reported mean represents.

The record’s adaptive-study description is another reason to distinguish a trial’s label from its analysis details. The registry does not explain adaptation procedures, interim analyses, or the statistical plan. Without those details, readers cannot assess how design adaptations may have been handled or whether multiplicity was controlled. The posted results should therefore be interpreted only as the described endpoint and safety summaries.

Finally, the record highlights the difference between planning and observed evidence. Its sample-size assumptions describe planning illustrations based on the observed effect, not the trial’s own design or observed power. For this continuous endpoint, two-arm planning values are recorded as missing or not estimable. These features reinforce that a small early-phase study can offer descriptive information while leaving comparative precision and design rationale unresolved.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The principal limitation for interpreting the primary endpoint is the small and uneven arm-level information, especially the placebo groups with one participant each. Their means are individual observations rather than stable estimates of a group average, and their standard deviations are not reported. The VH3739937 group summaries also show substantial variability, and no confidence intervals are provided.

The record reports no inferential analysis for the primary endpoint. There is no comparative estimate, statistical test, or uncertainty interval with which to judge the apparent differences among group means. The registry also does not report a multiplicity procedure, an interim analysis plan, or details of the adaptive design. These omissions prevent assessment of how the overall testing strategy was intended to control error or how any adaptation affected inference.

The endpoint captures a maximum change through Day 8, not a fixed-visit value or a longer-term outcome. The record states that only participants with data at the specified timepoints were included, but detailed missing-data handling and sensitivity analyses are not reported. It also does not provide a participant-flow account by arm for the primary analysis.

The study is marked terminated, but the reason for termination is not reported in the registry record. The registry entries do not establish whether termination affected recruitment, follow-up, or planned analyses. Demographic detail beyond the stated population, the protocol’s sample-size justification, and results for the listed secondary outcomes are not reported in the information. These limitations constrain interpretation to the short-term descriptive data that are posted.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: A Study to Investigate the Antiviral Effect, Safety, Tolerability and Pharmacokinetics of VH3739937 in in Treatment-Naive Adults Living With HIV-1 — NCT06061081.
• Registry record last updated 2025-10-20; status last verified 2025-09.
• Results first posted 2025-10-20.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

NCT06061081 is a randomized, parallel-group, placebo-controlled phase 2 study of VH3739937 in treatment-naive adults living with HIV-1. It is classified as quadruple-masked, while the official title describes double-blinding with the sponsor unblinded and an adaptive design. Enrollment is recorded as 21, and the study status is terminated. The registry lists a start date of 2023-12-21 and a primary completion date of 2024-08-27.

The primary endpoint is maximum change from baseline in plasma HIV-1 RNA through Day 8. The registry posts arm-level means and standard deviations where available, plus safety counts. It reports no analysis entries or inferential comparisons for the primary endpoint. The reason for termination, detailed adaptive procedures, multiplicity handling, and additional missing-data methods are not reported in the registry record.